Samay

COPD will cost $61 billion per year by 2029, but no technologies can evaluate lung function from home, leaving patients and doctors to rely on questionnaires. Samay will disrupt the remote diagnostic market just as Dexcom did with Diabetes and iRhythm with cardiac arrhythmias. Our chest patches use a patented technology that diagnoses COPD with 90% accuracy and detects exacerbation biomarkers with 83% accuracy, passively. We're building an AI-assisted management and diagnostic platform to accompany patients and doctors throughout the care continuum, from exacerbation detection to determining effective therapies for more personalized care, all from home.

Samay headquartered in United States, North America, operates in the Artificial Intelligence (AI), Machine Learning, Wearables, Health Diagnostics sector. The company focuses on Artificial Intelligence (AI) and has secured $1.4B in funding across 288 round(s). With a team of 11-50 employees, Samay is actively contributing to advancements in Artificial Intelligence (AI). Their latest funding round, Grant - Samay, raised $500.0K. Discover more about their projects, partnerships, and impact on our platform.